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Abstract
Background: A previous genome-wide association study identified 2 susceptibility loci for severe dengue at MICB
rs3132468 and PLCE1 rs3740360 and further work showed these mutations to be also associated with less severe clinical
presentations. The aim of this study was to determine if these specific loci were associated with laboratory features of
dengue that correlate with clinical severity with the aim of elucidating the functional basis of these genetic variants.
Methods: This was a case-only analysis of laboratory-confirmed dengue patients obtained from 2 prospective cohort
studies and 1 randomised clinical trial in Vietnam (Trial registration: ISRCTN ISRCTN03147572. Registered 24th July 2012).
2742 dengue cases were successfully genotyped at MICB rs3132468 and PLCE1 rs3740360. Laboratory variables were
compared between genotypes and stratified by DENV serotype.
Results: The analysis showed no association between MICB and PLCE1 genotype and early viraemia level, platelet nadir,
white cell count nadir, or maximum haematocrit in both overall analysis and in analysis stratified by serotype.
Discussion: The lack of an association between genotype and viremia level may reflect the sampling procedures within
the included studies. The study findings mean that the functional basis of these mutations remains unclear.
Trial registration: ISRCTN ISRCTN03147572. Registered 24th July 2012.
Background
Dengue viruses (DENV) cause a spectrum of clinical man-
ifestations ranging from asymptomatic infection through
to life-threatening shock and haemorrhage [1, 2]. Single
nucleotide polymorphisms (SNPs) at two genomic loci are
associated with DSS in Vietnamese children [3]. These
SNPs were in the major histocompatibility complex class I
polypeptide-related sequence B gene (MICB) on chromo-
some 6 (rs3132468) and in the phospholipase C epsilon 1
(PLCE 1) gene on chromosome 10 (rs3740360). Further
work demonstrated that these variations are also signifi-
cantly associated with less severe but medically attended
dengue cases dengue [4, 5]. The MICB gene encodes a
surface protein that contributes to natural killer (NK) cell
activation. The observed association with a SNP in the
MICB gene and dengue shock syndrome (DSS) may
reflect dysfunctional NK and CD8 cell activity in severe
disease, suggesting a key role for these cells in disease con-
trol and pathogenesis. Mutations in PLCE1 are associated
with nephrotic syndrome, a condition characterised by
proteinuria, reduced vascular oncotic pressure and subse-
quent oedema [6]. The association with mutations in
PLCE1 and dengue raises the possibility of a role for this
gene in the maintenance of normal endothelial integrity.
Despite these speculations, the functional basis for the
association of these mutations with DSS remains unclear.
The aim of this study was to measure if an association
existed between the aforementionedMICB and PLCE1 spe-
cific mutations and virological and hematological features
of dengue that have been shown to have correlation with
the clinical outcome of infection. For example, the level of
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viremia in the first days of illness is positively associated
with the severity of the disease phenotype [7]. Similarly, the
degrees of lymphopenia and thrombocytopenia are associ-
ated with development of DSS [8, 9]. Thus this study tested
the hypothesis that the MICB (rs3132468) and PLCE1
(rs3740360) variants were associated with clinically import-
ant laboratory features of dengue.
Methods
The specific aims of this analysis were to measure the asso-
ciation between individuals with different MICB rs3132468
and PLCE1 rs3740360 genotypes (wild-type, heterozygous
carriers, and homozygous variant) and various laboratory
features. The laboratory features that were compared
between the groups were (1) early plasma viremia level, (2)
platelet nadir, (3) white cell count nadir, and (4) maximum
haematocrit.
Samples were obtained from participants who gave written
informed consent to participate in the previously reported
prospective studies detailed in Table 1 [10–12]. Parents or
guardians of the children involved in the studies gave written
informed consent on their behalf. All these studies took place
in southern Vietnam. The protocols of these studies were
reviewed and approved by the Institutional Review Boards of
each study site (Hospital for Tropical Diseases Ho Chi Minh
City (HCMC), Children’s Hospital 1 and 2 HCMC, and Tien
Giang Hospital) and by the Oxford University Tropical Re-
search Ethics Committee. The inclusion criteria for 13DX
were (1) fever or history of fever for less than 72 h, (2) clinical
suspicion of dengue, (3) 1–15 years of age, (4) written in-
formed consent, and (5) accompanying family member has a
mobile phone. The exclusion criteria were (1) deemed
unlikely to attend follow-up, and (2) in whom an alternative
diagnosis was thought more likely. The inclusion criteria for
22DX were (1) fever or history of fever for less than 72 h, (2)
clinical suspicion of dengue, (3) aged 5 years or over, (4) writ-
ten informed consent. The exclusion criteria were (1) localis-
ing features suggesting an alternative diagnosis, and (2)
inability to attend daily follow-up. The inclusion criteria for
26DX were (1) age 18 or over, (2) presenting within 72 h of
fever onset with an illness consistent with dengue, (3) positive
rapid test for dengue non-structural protein 1 (NS1 (NS1
Ag-STRIP, Bio-Rad). The exclusion criteria were (1) alanine
transaminase (ALT) level > 150 U/L, (2) creatine kinase (CK)
level > 1000 U/L, (3) platelet count <50 × 109/L, (4) preg-
nancy or lactation, and (5) a history of cirrhosis or myopathy.
This was a case-only analysis of laboratory-confirmed
dengue patients obtained from two prospective cohort
studies and one randomised clinical trial in Vietnam.
The cohort studies were conducted in both adults and
children and aimed to create diagnostic and prognostic
algorithms to improve the clinical management of den-
gue in this setting. The randomised clinical trial was an
investigation of lovastatin therapy in adult patients with
dengue (Trial registration: ISRCTN03147572) [10].
DNA extractions were performed using a MagNA Pure
96 DNA and Viral NA Small Volume Kit (Roche,
Germany) according to the manufacturer’s instructions.
Candidate SNPs were genotyped using a TaqMan genotyp-
ing assay to amplify and detect the specific alleles in the
DNA samples as per the manufacturer instructions. Sam-
ples failing picogreen QC (<5 ng/uL in concentration)
were excluded from further analysis. Similarly, during the
genotyping process, samples, which fail to show adequate
allelic discrimination on the Taqman RT-PCR melt-curve,
were also excluded from analysis. Each SNP has been
shown previously to show good call rate exceeding >95%.
Statistical analysis was performed in Stata 13 (Stata
Statistical Software: Release 13. College Station, TX.
StataCorp LP). Laboratory variables were compared be-
tween genotypes and stratified by DENV serotype using
the binary chi-squared test, the Kruskal-Wallis non-
parametric test and the analysis of variance test. A sample
size calculation was not performed, as a priori, the vari-
ance of the viremia measurements was not known.
Results
Two thousand seven hundred forty two dengue cases were
successfully genotyped at MICB rs3132468 and PLCE1
rs3740360. 573 cases were in adults (age ≥ 15) and 2180
were in children. There were 109 cases of severe dengue
across the cohorts (6 in adults and 103 in children). The
baseline characteristics of the study participants are sum-
marised in Table 2.
Association between MICB rs3132468 and enrolment viremia
The mean viremia was compared between patients with
the spectrum of MICB genotypes. The mean viremia in
patients carrying the C/C allele was 7.16 (95% CI: 6.84–
7.47) log10-copies/mL. In those with the C/T allele it was
7.05 (95% CI: 6.92–7.18) log10-copies/mL, and in those
with the T/T allele it was 7.08 (95% CI: 7.01–7.15) log10-
Table 1 Details of studies included in analysis
Study Setting Study type Age criteria
(years)
Number
(% male)
Laboratory sampling
procedure
Median age
(range 5th–95th centile)
13DX Outpatient Prospective cohort 1–15 1951 (57) Enrolment only 9 (3–14)
22DX Outpatient Prospective cohort 5 or over 749 (60) Multiple time points 18 (6–39)
26DX Inpatient Randomised clinical trial 18 or over 42 (57) Multiple time points 24 (18–51)
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copies/mL. The difference between these values was not
statistically significant. The comparison in viremia levels
betweenMICB genotypes was repeated with data stratified
by DENV serotype. Again, no significant differences were
demonstrated. These data are summarised in Table 3.
Collectively, these data indicate some variation in the
viremia between the serotypes but no significant differ-
ence between theMICB genotypes.
Association between PLCE1 rs3740360 and enrolment
viraemia
The mean viremia was compared between the PLCE1
genotypes. The mean viremia in patients carrying the A/A
allele was 7.08 (95% CI: 7.00–7.15) log10-copies/mL. In those
carrying the A/C allele it was 7.09 (95% CI: 6.99–7.19) log10-
copies/mL, and in those with the C/C allele it was 7.02 (95%
CI: 6.78–7.26) log10-copies/mL. The difference between
these values was not statistically significant. The comparison
in viremia levels between PLCE1 genotypes was repeated
with data stratified by DENV serotype. Again, no significant
differences were demonstrated. These data are summarised
in Table 3. As above, these data indicate some variation in
the viremia level between the serotypes but no significant
difference between the PLCE1 genotypes.
Association between MICB rs3132468 and other
laboratory variables
After excluding data from 13DX, which only included
enrolment results, the platelet nadir, the maximum
haematocrit and the minimum white cell count were
Table 2 Collated study population characteristics (n = 2730)
DENV1 (n = 1042) DENV2 (n = 593) DENV3 (n = 263) DENV4 (n = 832) All (n = 2730)
Age (median, IQR), years 10(7–13) 10(7–14) 9(6–13) 11(8–15) 10(7–14)
Sex (n,%)
Male 596(57.2) 357(60.2) 147(55.9) 474(57.0) 1574(57.7)
Female 446(42.8) 236(39.8) 116(44.1) 358(43.0) 1156(42.3)
Days of illness at enrolment (n,%)
0 9(0.86) 1(0.17) 0(0) 3(0.36) 13(0.48)
1 323(31.0) 174(29.3) 85(32.3) 195(23.4) 777(28.5)
2 437(41.9) 271(45.7) 113(43.0) 354(42.5) 1175(43.0)
3 269(25.8) 146(24.6) 64(24.3) 279(33.5) 758(27.8)
4 2(0.19) 1(0.17) 1(0.4) 0(0) 4(0.15)
Viremia (mean, 95% CI), log10 copies/mL 7.39(7.29–7.50) 6.89(6.77–7.01) 7.14(6.94–7.33) 6.80(6.71–6.88) 7.08(7.02–7.14)
Clinical classification (n,%)
Dengue 950(91.2) 553(93.3) 257(97.7) 780(93.8) 2540(93.0)
Severe dengue 39(3.74) 32(5.4) 6(2.3) 32(3.85) 109(3.99)
Table 3 Viremia by MICB and PLCE genotype by dengue serotype and overall (mean (IQR) (N))
MICB
Serotype C/C C/T T/T P-value
DENV1 7.32 (6.7–7.95) (n = 24) 7.28 (7.03–7.53) (n = 211) 7.43 (7.31–7.55) (n = 761) 0.238
DENV2 7.04 (6.32–7.76) (n = 18) 7.03 (6.77–7.29) (n = 125) 6.84 (6.7–6.98) (n = 450) 0.833
DENV3 6.99 (5.24–8.75) (n = 7) 7.15 (6.7–7.6) (n = 50) 7.14 (6.91–7.36) (n = 206) 0.836
DENV4 7.13 (6.67–7.59) (n = 28) 6.75 (6.56–6.93) (n = 184) 6.8 (6.7–6.9) (n = 620) 0.86
Overall 7.16 (6.84–7.47) (n = 78) 7.05 (6.92–7.18) (n = 583) 7.08 (7.01–7.15) (n = 2081) 0.315
PLCE
Serotype A/A A/C C/C P-value
DENV1 7.38 (7.24–7.53) (n = 578) 7.39 (7.22–7.56) (n = 397) 7.47 (7.03–7.91) (n = 67) 0.972
DENV2 6.83 (6.67–7) (n = 334) 6.99 (6.79–7.19) (n = 215) 6.83 (6.38–7.29) (n = 44) 0.938
DENV3 7.08 (6.82–7.34) (n = 157) 7.19 (6.87–7.5) (n = 87) 7.32 (6.35–8.29) (n = 19) 0.198
DENV4 6.87 (6.75–6.98) (n = 472) 6.74 (6.99–7.19) (n = 306) 6.51 (6.18–6.83) (n = 54) 0.867
Overall 7.08 (7–7.15) (n = 1546) 7.09 (6.99–7.19) (n = 1012) 7.02 (6.78–7.26) (n = 184) 0.7
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compared between the MICB genotypes in both an overall
analysis and then stratified by serotype. The median plate-
let nadir in patients with the C/C allele was 82.5 (IQR:
47–101) × 109/L, in those with the C/T allele was 80 (IQR:
48–115) × 109/L, and in those with the T/T allele was 70
(41–113) × 109/L. These differences were not statistically
significant. The minimum white cell count in those with
the C/C allele was 2.6 (IQR: 2.3–3.1) × 109/L, in those
with the C/T allele was 2.9 (IQR: 2.3–3.8) × 109/L and in
those with the T/T allele was 2.7 (IQR: 2.1–3.4) × 109/L.
These differences were not statistically significant. The
median maximum haematocrit in patients with the C/C
allele was 45.4% (IQR: 44–49.2%), in those with the C/T
allele was 45% (IQR: 42–48.3%), and in those with the T/T
allele was 44.7% (IQR: 41.8–48.4%). These differences
were not statistically significant. When these data were
stratified by DENV serotype again no significant differ-
ences were demonstrated. These data suggest no measur-
able association between MICB genotype and the
laboratory variables explored in this analysis.
These data are summarised in Table 4.
Association between PLCE1 rs3740360 and other
laboratory variables
The platelet nadir, the maximum haematocrit and the
minimum white cell count were compared between the
PLCE1 genotypes in both an overall analysis and then
stratified by serotype. The median platelet nadir in pa-
tients with the A/A allele was 71 (IQR: 41–109) × 109/L,
in those with the A/C allele was 76.5 (IQR: 45–118) ×
109/L, and in those with the C/C allele was 66 (37–114)
× 109/L. These differences were not statistically signifi-
cant. The minimum white cell count in those with the
A/A allele was 2.7 (IQR: 2.1–3.4) × 109/L, in those with
the A/C allele was 2.8 (IQR: 2.2–3.6) × 109/L and in
those with the C/C allele was 2.9 (IQR: 2.2–3.6) × 109/L.
These differences were not statistically significant. The
median maximum haematocrit in patients with the A/A
allele was 44.6% (IQR: 41.9–48.1%), in those with the A/
C allele was 45.1% (IQR: 42–48.3%), and in those with
the C/C allele was 45% (IQR: 42.4–50.3%). These differ-
ences were not statistically significant. When these data
were stratified by DENV, serotype again no significant
differences were demonstrated. These data suggest no
measurable association between PLCE1 genotype and
the laboratory variables explored in this analysis.
These data are summarised in Table 4.
Discussion
This study did not find an association between MICB and
PLCE genotype and early viremia level, platelet nadir, white
cell count nadir or maximum haematocrit in both overall
analysis and in analysis stratified by serotype. Given the
possibility that MICB may have an important role in the
establishment of antiviral effector function we proposed
that mutations in this gene might be associated with higher
dengue viraemia. Our analysis in 2742 adults and children
with dengue showed no difference in the enrolment
viraemia levels between the different MICB and PLCE1
genotypes in both an overall analysis and analysis stratified
by DENV serotype. The enrolment viremia was taken in
the vast majority of patients in the first 72 h of clinical
illness (Table 2). While our understanding of DENV
kinetics suggests that this is likely to correspond near to the
peak viraemia level it only gives a snapshot of the in vivo
viral dynamics. It is possible that the viral clearance
patterns varied across genotypes. In addition, measuring
plasma viremia only provides a surrogate of what is
happening in other tissues – obviously, however, invasive
assessments of this would not be appropriate in large pro-
spective studies. However, an interesting finding was the
range of early viraemia levels across the DENV serotypes
and between the different MICB and PLCE genotypes.
While the observed variation was not statistically signifi-
cant, it does suggest that there are factors that influence the
early viremia level. This may be a combination of intrinsic
genetic susceptibility, host immune status and various viral
factors [13]. Determining the factors that influence the
DENV “set point” would be intriguing and would advance
our understanding of dengue pathogenesis.
Table 4 Laboratory features by MICB and PLCE genotype
MICB
Laboratory/clinical feature C/C (n = 18) C/T (n = 150) T/T (n = 554) P-value
Platelet nadir (median(IQR)) 82.5 (47–101) 80 (48–115) 70 (41–113) 0.494
Minimum white cell count (median(IQR)) 2.6 (2.3–3.1) 2.9 (2.3–3.8) 2.7 (2.1–3.4) 0.214
Maximum haematocrit (median(IQR)) 45.4 (44–49.2) 45 (42–48.3) 44.7 (41.8–48.4) 0.244
PLCE
Laboratory/clinical feature A/A (n = 409) A/C (n = 266) C/C (n = 47) P-value
Platelet nadir (median(IQR)) 71 (41–109) 76.5 (45–118) 66 (37–114) 0.675
Minimum white cell count (median(IQR)) 2.7 (2.1–3.4) 2.8 (2.2–3.6) 2.9 (2.2–3.6) 0.268
Maximum haematocrit (median(IQR)) 44.6 (41.9–48.1) 45.1 (42–48.3) 45 (42.4–50.3) 0.336
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As no associations between viremia and genotype were
shown, it is perhaps not surprising that no associations
were demonstrated between genotype and the pre-
selected routine haematological laboratory variables both
in overall analysis and in analysis stratified by DENV
serotype. These variables were chosen because they have
been previously shown to have some correlation with
dengue severity [8, 9]. However, differences in the study
designs, particularly the frequency of laboratory investi-
gations, across the cohorts described meant that the lar-
gest study in terms of patient numbers (13DX) was
excluded from this component of the analysis.
While previous work has demonstrated an association
between genetic variants of MICB and PLCE1 and both
severe and non-severe dengue, the functional basis of
these associations is not clear [3, 4]. MICB encodes an ac-
tivating ligand for natural killer cells, and possibly CD8+
T cells, raising the possibility that mutations in this gene
may result in altered antiviral effector functions and an as-
sociated increased viral burden, a recognised risk factor
for the development of severe dengue [7]. It is possible
that the associations reflect an aspect of dengue pathogen-
esis unrelated to control of early viral replication. The as-
sociation of PLCE1 and dengue is harder to explain. It is
interesting to note that mutations in this gene have been
associated with nephrotic syndrome, regulation of blood
pressure and oesophageal malignancy [6, 14, 15]. While it
is plausible that the relationship between mutations in
PLCE1 and both severe dengue and nephrotic syndrome
suggests some role in the maintenance of endothelial in-
tegrity, it is more difficult to relate this potential function
to oesophageal malignancy. The role of PLCE1 in control
of blood pressure warrants further exploration as it raises
the possibility of some overlap in function in dengue given
hypotension is seen in severe dengue. While the
hypotension in dengue shock is mediated largely by
plasma leak, it is possible that variants in PLCE1 play a
contributory role. This relationship with diverse condi-
tions suggests an important, but as yet unclear, role for
PLCE1 in human health and disease.
Our study has limitations. The number of patients with
the “risk” alleles for MICB and PLCE1 was relatively small,
reflecting the low frequency of these allelic variants. The
small number of cases may mean that the analysis lacked
the power to detect a true association. This is especially
true as the dose effect of a given SNP is likely to be small.
Further work with a larger sample size may allow further
exploration of a potential dose effect of a homozygous
allelic variant on initial viremia. In addition, the study
methodology varied between the studies included in the
analysis meaning that it was only possible to explore the
relationship between genotype and laboratory variable in a
smaller group of patients. The functional basis of these
observed associations remains unclear but it is possible
that pooled data from prospective intervention studies will
provide clearer insights. The potential offered by this
study approach reflects the more frequent sampling that
typically occurs in this type of study. It would be intri-
guing to explore whether these associations have an effect
on cytokine levels – this could be explored within the
context of prospective studies. Greater insights into
dengue host susceptibility have the potential to expand
our knowledge of disease pathogenesis and, in the longer
term, assist the development of vaccines and therapeutics.
Conclusions
This study aimed to explore the functional basis of specific
mutations in theMICB and PLCE1 genes previously shown
to be associated with severe dengue. We assessed whether
these specific loci were associated with laboratory features
of dengue that correlate with clinical severity. Our analysis
showed no association betweenMICB and PLCE1 genotype
and early viraemia level, platelet nadir, white cell
count nadir, or maximum haematocrit in both overall
analysis and in analysis stratified by serotype. These
results mean that the functional basis of these
mutations remains unclear. It is possible that greater
insights into dengue susceptibility and pathogenesis
will be gained from careful analysis conducted within
prospective studies.
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